Floatz logo

Dfn-15

Postpartum Depression

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPhase 3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Postpartum Depression cohort.

Asset / SponsorPhaseRating
ALLOPREGNAN-3.ALPHA.-OL-20-ONE
Supernus Pharmaceuticals, Inc.
Phase 3BBB
Sertraline
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 4BB
Zuranolone
Biogen
Phase 3BB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Stanford University
Phase 4BB
Cipralex
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3BB

View all 12 →

Same molecule, other indications

Dfn-15 is also rated in:

osteoarthritis, hipDormant
BB
Indicative ·
71 / 100
View asset →
osteoarthritis, kneeDormant
BB
Indicative ·
69 / 100
View asset →
ArthritisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →